Special Issue "Personalized Medicine for COVID-19"
Deadline for manuscript submissions: 29 February 2024 | Viewed by 235
Interests: human genetics and COVID-19 symptoms and severity; molecular evolution of SARS-CoV-2; reinfections; vaccines and anti-virals; long COVID-19; SARS-CoV-2 ecology and host-virus interactions; ethical issues in infectious diseases
2. Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain P.O. Box 15551, United Arab Emirates
3. Clinical Bioinformatics Unit, Department of Pathology, School of Medicine and Health Sciences, Erasmus University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands
Interests: pharmacogenomics; personalized therapeutics; clinical care; clinical implementation; clinical studies; pharmacogenomic testing; health technoloigy assessment; regulatory guidance
Special Issues, Collections and Topics in MDPI journals
Special Issue in International Journal of Molecular Sciences: Advances in Hematological Disorders: New Insights and Novel Methods
Special Issue in Future Pharmacology: Personalized Therapeutics Worldwide: Clinical Reality and Future Challenges
Special Issue in Pharmaceutics: Personalized Therapeutics Worldwide: Clinical Reality and Future Challenges
Personalized medicine is progressively gaining momentum in modern healthcare in lieu of the traditional “one-size-fits-all” approach. Recent technological advances, particularly in genomic sequencing, have contributed significantly to this end. The impressive heterogeneity of clinical manifestations of infections with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and potential long-term consequences of coronavirus disease 2019 (COVID-19), showcase the likely advantages of applying personalized medicine for COVID-19. However, despite the “COVIDation” of medicine, very few studies have been published to date to address the issue. The articles that will be published pertain to, but may not be limited to, the interplay of host and viral factors in the following topics:
- COVID-19 severity
- Long-COVID symptoms and severity
- Response and duration of protection of COVID-19 vaccines
- Response to therapy and development of resistance to anti-virals
- Ethical implications of applying precision medicine for COVID-19
Dr. Cleo Anastassopoulou
Prof. Dr. George P. Patrinos
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- COVID-19 severity
- long-COVID symptoms and severity
- response and duration of protection of COVID-19 vaccines
- response to therapy and development of resistance to anti-virals
- ethical implications of applying precision medicine for COVID-19